WO2016176152A3 - Re-targeted foamy virus vectors - Google Patents

Re-targeted foamy virus vectors Download PDF

Info

Publication number
WO2016176152A3
WO2016176152A3 PCT/US2016/029251 US2016029251W WO2016176152A3 WO 2016176152 A3 WO2016176152 A3 WO 2016176152A3 US 2016029251 W US2016029251 W US 2016029251W WO 2016176152 A3 WO2016176152 A3 WO 2016176152A3
Authority
WO
WIPO (PCT)
Prior art keywords
retargeted
vectors
cells
foamy virus
targeted
Prior art date
Application number
PCT/US2016/029251
Other languages
French (fr)
Other versions
WO2016176152A2 (en
Inventor
Grant D. Trobridge
Original Assignee
Washington State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington State University filed Critical Washington State University
Publication of WO2016176152A2 publication Critical patent/WO2016176152A2/en
Publication of WO2016176152A3 publication Critical patent/WO2016176152A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/17011—Spumavirus, e.g. chimpanzee foamy virus
    • C12N2740/17041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/17045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/17011—Spumavirus, e.g. chimpanzee foamy virus
    • C12N2740/17051—Methods of production or purification of viral material
    • C12N2740/17052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/40—Vector systems having a special element relevant for transcription being an insulator

Abstract

Provided herein are retargeted foamy virus (FV) vectors, including insulated retargeted FV vectors such as 650cHS4, Al, and A2 insulator retargeted FV vectors that exhibit high, clinically significant titers, favorable safety profiles, and reduced genotoxicity. The retargeted FV vectors disclosed herein may be suitably employed for therapeutic applications, in particular gene therapy applications, which involve the ex vivo and/or in vivo delivery of a gene of interest to a wide variety of target cells, including hematoietic cells, such as hematopoietic progenitor cells and stem cells (HSCs).
PCT/US2016/029251 2015-04-25 2016-04-25 Re-targeted foamy virus vectors WO2016176152A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562152876P 2015-04-25 2015-04-25
US62/152,876 2015-04-25

Publications (2)

Publication Number Publication Date
WO2016176152A2 WO2016176152A2 (en) 2016-11-03
WO2016176152A3 true WO2016176152A3 (en) 2016-12-22

Family

ID=57199447

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/029251 WO2016176152A2 (en) 2015-04-25 2016-04-25 Re-targeted foamy virus vectors

Country Status (1)

Country Link
WO (1) WO2016176152A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201617599D0 (en) * 2016-10-18 2016-11-30 Univ Leuven Kath MLV-based gene therapy with mutated integrase coupled to peptides
US20200255860A1 (en) * 2017-09-18 2020-08-13 Children's Hospital Medical Center A strong insulator and uses thereof in gene delivery

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080153770A1 (en) * 2006-10-10 2008-06-26 Viromed Co., Ltd. Expression Vectors with Improved Safety

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080153770A1 (en) * 2006-10-10 2008-06-26 Viromed Co., Ltd. Expression Vectors with Improved Safety

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TOBALY-TAPIERO ET AL.: "Chromatin tethering of incoming foamy virus by the structural Gag protein.", TRAFFIC, vol. 9, no. 10, 2008, pages 1717 - 1727, XP055337738 *

Also Published As

Publication number Publication date
WO2016176152A2 (en) 2016-11-03

Similar Documents

Publication Publication Date Title
WO2016170348A3 (en) Sarna compositions and methods of use
PH12020551744A1 (en) Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues
MX2023004479A (en) Multiple vector system and uses thereof.
EP3679148A4 (en) Lipid nanoparticle formulations of non-viral, capsid-free dna vectors
MX2020011939A (en) Novel crispr enzymes and systems.
WO2017191274A3 (en) Rna encoding a therapeutic protein
MX2020003413A (en) Preparation and storage of liposomal rna formulations suitable for therapy.
WO2016137235A3 (en) Pharmaceutical composition for treating cancer comprising microrna as active ingredient
WO2015048345A3 (en) Compositions and formulations for prevention and reduction of tumorigenesis, cancer cell proliferation and invasion, and methods of production and use thereof in cancer treatment
WO2015155686A3 (en) Methods and compositions for rna-directed repression of transcription using crispr-associated genes
WO2017044857A3 (en) Methods and compositions for the treatment of glaucoma
MX367100B (en) Aav vector compositions and methods for gene transfer to cells, organs and tissues.
WO2015075557A3 (en) C/ebp alpha short activating rna compositions and methods of use
MY172292A (en) Vectors and sequences for the treatment of diseases
MX365711B (en) Effective delivery of large genes by dual aav vectors.
WO2016149455A3 (en) The rna interactome of polycomb repressive complex 1 (prc1)
WO2017112528A3 (en) Interleukin-15 compositions and uses thereof
WO2014205317A3 (en) Cyclic peptides as protein targeting agents
WO2013063383A3 (en) Vectors encoding rod-derived cone viability factor
WO2011140595A3 (en) Immunostimulatory and vaccine compositions
WO2019056015A3 (en) A strong insulator and uses thereof in gene delivery
WO2016086227A3 (en) Therapeutic compositions comprising transcription factors and methods of making and using the same
EP3998341A3 (en) Adenoviral vectors
WO2016205323A8 (en) Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
WO2017001570A3 (en) Atp-binding cassette family coding polyribonucleotides and formulations thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16786973

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16786973

Country of ref document: EP

Kind code of ref document: A2